Neumarker

Neumarker, in collaboration with a research team from University of California, San Francisco (UCSF), has been awarded a research grant from the California Initiative to Advance Precision Medicine (CIAPM) for their project, “Precision Mental Health to Predict Risk, Prevent, and Treat Depression in Publicly Funded Youth.” Led by UCSF’s Professor Tony Yang, the project focuses on identifying youth at risk for depression, testing neuroscience-based prevention methods, and creating an online dashboard to assist clinicians in selecting optimal treatment plans.

Securing the CIAPM grant underscores the strength of the biomarker platform of Neumarker. The company is poised to develop EEG biomarkers that will enable precise, effective interventions in depression care.

This project is one of three selected for up to $3 million in funding over three years and aims to leverage UCSF’s clinical expertise with Neumarker’s advanced AI-driven EEG technology, bringing personalized mental health care to adolescent patient population in California.

About CIAPM: https://lci.ca.gov/ciapm/

For more information, please contact:
Ken Wang. Ph.D.
Co-Founder and CEO
Neumarker Inc.
ken.wang@neumarker.ai

About Neumarker
Neumarker is committed to advancing precision neuro-medicine through collaborations with drug developers, clinicians, and academic researchers. Our cutting-edge brain biomarker discovery platform, powered by AI, aims to revolutionize CNS disorder treatment by personalizing treatment for each patient and accelerating drug development through efficient clinical trials. To learn more, visit www.neumarker.ai.